NewsBenzingaMedicus Pharma soumet à la FDA un protocole optimisé et fluide de phase 2b/3 à visée d’enregistrement pour le teverelix dans le traitement du cancer avancé de la prostate Medicus Pharma soumet à la FDA un protocole optimisé et fluide de phase 2b/3 à visée d’enregistrement pour le teverelix dans le traitement du cancer avancé de la prostate Benzinga 2026.09.29 11:31 (GMT+0) Open on Benzinga Other news NVIDIA Interim CEO Colette Kress Says Vera Rubin Is Off To An Explosive Start, Our Roadmap Is On Track And Our Ambition Has Never Been Greater Auna Q3 Adj. EPS $0.12 Misses $0.27 Estimate, Sales $386.000M Beat $362.630M Estimate Here’s How Much You Would Have Made Owning Marvell Technology Stock In The Last 20 Years NVIDIA Sees Q4 Sales $126.100B-$133.900B vs $125.163B Est NVIDIA Q3 Adj. EPS $2.68 Beats $2.48 Estimate, Sales $115.844B Beat $109.080B Estimate Auna Affirms FY2026 Sales Guidance of $1.573B-$1.630B
NVIDIA Interim CEO Colette Kress Says Vera Rubin Is Off To An Explosive Start, Our Roadmap Is On Track And Our Ambition Has Never Been Greater